Award
National Cancer Institute 1R21CA303173-01
Targeting tumor microenvironment-mediated radiopharmaceutical therapy resistance in prostate cancer
Recipient
University of California Los Angeles
Award Amount
$404,972.00
Ceiling
$404,972.00
Awarded
July 23, 2025
Identifier
1R21CA303173-01
NIH grant awarded to University of California Los Angeles to study mechanisms of resistance to radiopharmaceutical therapy in prostate cancer, focusing on tumor microenvironment and immune response modulation.
Description
This project investigates how ENPP1 expression affects the immune response to PSMA-targeted radiopharmaceutical therapy in prostate cancer, aiming to develop combination therapies to overcome resistance. The research focuses on defining mechanisms that limit durable radiopharmaceutical therapy responses, particularly the role of cGAMP signaling and ENPP1 expression in tumor immune microenvironment modulation.